Obermatt
See Similar Stocks →

OptimizeRx

NAQ:OPRX · US68401U2042
Health Care TechnologySmall

360

82
EV / EBIT38
Price / Owner Earnings28
Owner Earnings Yield86
Dividend Yield1
Price/Sales84
EV / Gross Profit74
Price/Book93
Return on Capital71
Cash Return on Capital69
Return on Equity59
EBIT Margin85
Gross Profitability74
Cash Conversion72
Accruals59
Owner Earnings Margin82
Sales growth10
Profit Growth38
Long-Term EPS Growth91
Reinvestment15
Price momentum4
Debt load53
Refinancing93
Debt Payback48
Liquidity61
Analyst ratings83
Opinion Changes50
Price Target Upside74
Market mood82
Value Creation12/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

OptimizeRx clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryHealth Care Technology
SizeSmall
TypePublic Company
ExchangeNASDAQCM
Employees117
Websiteoptimizerx.com
ISINUS68401U2042
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)
Themes
Machine LearningCustomer AnalyticsPredictive AnalyticsDigital WellnessMarketing AutomationArtificial IntelligenceBiotechnologyHealth CareMedical Device

Description

OptimizeRx Corporation (‘OptimizeRx’) operates as a digital healthcare technology company. The company leverages its proprietary technology solutions and partnerships to help its clients develop and execute highly individualized and targeted marketi…

Analysis

Quality compounder

OptimizeRx Corporation is a quality compounder: a well-run business trading at a price that reflects what it is worth.

The price is attractive. You pay 8.9× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.

The trajectory is tepid and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value.

What to watch: A large part of the company's book value is the price paid for past acquisitions. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
91
2023202420252026

All-time high

91

Jun 2026

All-time low

59

Jan 2025

Average rank

78

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
84
72
49
25
Price/Earnings
74
60
44
43
Price/Book
93
84
59
36
Dividend Yield
1
1
1
1
Value (overall)
88
63
35
23

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare OptimizeRx with its peers
Impinj
NSQ:PI
9
CountryUSA
IndustrySemiconductors & Semiconductor Equipment
SizeMedium
Full Stock Analysis →
Phreesia
NYQ:PHR
70
CountryUSA
IndustryHealth Care Technology
SizeMedium
Full Stock Analysis →
CareCloud
NMQ:CCLD
98
CountryUSA
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →
DarioHealth
NAQ:DRIO
20
CountryUSA
IndustryHealth Care Technology
SizeSmall
Full Stock Analysis →
Lattice Semiconductor
NSQ:LSCC
53
CountryUSA
IndustrySemiconductors & Semiconductor Equipment
SizeMedium
Full Stock Analysis →
Waystar
NSQ:WAY
74
CountryUSA
IndustryHealth Care Technology
SizeLarge
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →